Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319963 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
A Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and HPV-Related Cervical Carcinoma, sponsored by Theravectys S.A..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 4
- Study locations
NCT06319963 is a Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and HPV-Related Cervical Carcinoma that is actively recruiting participants, run by Theravectys S.A.. The registered enrollment target is 72 participants, below the 87-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (17% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06319963, a Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and HPV-Related Cervical Carcinoma, is actively recruiting participants, sponsored by Theravectys S.A..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.
Conditions Studied
Interventions
- DRUG Two IM injections Lenti-HPV-07
- DRUG One IM injection Lenti-HPV-07
Study Locations (4)
Florida
- Florida Cancer Specialists (from Sarah Canon research Institute) - Orlando
- Tampa General Hospital - Tampa
- Moffitt Cancer Center - Tampa
Oklahoma
- Oklahoma Cancer Specialists and Research Institute, LLC - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06319963
The ClinicalTrials.gov registry entry for NCT06319963 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (17% lower). The listed sponsor is Theravectys S.A., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HPV Positive Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Two IM injections Lenti-HPV-07 is the first listed.
NCT06319963 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06319963 about?
NCT06319963 is a clinical study titled "A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer". The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? ...
What is the current status of trial NCT06319963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-08-08. Estimated completion is 2026-12.
What conditions does trial NCT06319963 study?
This clinical trial studies the following conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma.
What interventions are being tested in trial NCT06319963?
The interventions under investigation include: Two IM injections Lenti-HPV-07 (DRUG), One IM injection Lenti-HPV-07 (DRUG).
Who is sponsoring clinical trial NCT06319963?
This trial is sponsored by Theravectys S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319963 being conducted?
This trial has 4 study locations across Florida, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
COMPLETED · Phase 1
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
HPV Positive Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
HPV-Related Cervical Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.